Craig A. Wheeler
President and Chief Executive Officer
Santiago Arroyo, M.D., Ph.D.
Senior Vice President, Development and Chief Medical Officer
Chief Human Resources and Infrastructure Officer
Chief Legal Officer and General Counsel
Ian D. Fier
Chief Manufacturing and Program Officer
Young Kwon, Ph.D.
Chief Business Officer
Anthony Manning, Ph.D.
Chief Scientific Officer
Chief Financial Officer
Mr. Wheeler joined Momenta as CEO in September of 2006. He led the company through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. He has overseen the company’s growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron BioPharmaceuticals where during his five-year tenure the pharmaceutical division’s global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector. He began his career at Merck’s MSDRL research unit. Mr. Wheeler is currently a member of the Board of Directors of Amicus Therapeutics as well as the Association for Accessible Medicines (AAM) where he previously served as Chairman from 2014 to February 2016. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion.
Dr. Arroyo joined Momenta in June of 2017. He is responsible for preclinical and clinical development and regulatory affairs. He joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer. Previously he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Cardiovascular and Metabolism, Pain, Neuroscience, Regenerative Medicine and Rare Diseases. He was previously Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and at the Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.
Ms. Beltramello joined Momenta in October of 2007. Ms. Beltramello is responsible for all human resources, IT, and facilities matters for the company. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.
Alejandra V. Carvajal, J.D., joined Momenta as Vice President, Deputy General counsel in June 2017 and has served as the company's Chief Legal Officer, General Counsel & Secretary since October 2018. Ms. Carvajal is responsible for all legal matters and operations at the company. Prior to joining Momenta, Ms. Carvajal was Vice President and General Counsel of Cerulean Pharma, a public biotechnology company, from September 2014 until June 2017. Prior to Cerulean, Ms. Carvajal worked at Millennium: The Takeda Oncology Company from 2004 to 2014, where she held a variety of legal positions of increasing seniority. Ms. Carvajal began her legal career in private practice with the law firms of Day, Berry &Howard and Hill & Barlow. Ms. Carvajal received a B.A. cum laude from Harvard University and a J.D. cum laude from Georgetown University Law Center.
Mr. Fier joined Momenta in October of 2002. Mr. Fier is responsible for overseeing our process development and quality functions, manufacturing, and program management. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA in Heath Care Management from Boston University.
Dr. Kwon joined Momenta in January of 2011. At Momenta, he is responsible for driving business and corporate development strategy, commercial analysis, investor relations and banking relations. He was previously Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. He has co-authored numerous peer-reviewed publications in the area of neurobiology.
Dr. Manning joined Momenta in January 2013. He is responsible for research and driving the discovery of novel products. Since joining Momenta, his teams have advanced three novel autoimmune drugs nipocalimab (M281), M230, and M254) into development and implemented a research engine to discover novel, first-in-class therapeutics for rare immune-related diseases. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals. Dr. Manning is currently a member of the Board of Directors for Palatin Technologies, and is the Chairman of the non-profit Institute for Biomedical Entrepreneurship. Dr. Manning holds a PhD from the University of Otago, New Zealand, and has authored more than 100 peer-reviewed publications and patents in the fields of signal transduction, autoimmune diseases and drug discovery.
Ms. Robertson joined Momenta in May 2017 as Vice President, Financial Planning and Analysis and has served since October 2018 as Chief Financial Officer. Ms. Robertson is responsible for the oversight of all finance, accounting and treasury. Prior to joining Momenta, Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., following its spin-out from Baxter International in July 2015. Before that, Ms. Robertson was at Ironwood Pharmaceuticals as head of Financial Planning and Analysis and Operations, and prior to that, Genzyme Corporation where she held various leadership positions in the Oncology and Biosurgery divisions with Finance and Commercial Operations, focusing on financial analysis for business development, acquisition integrations, and divestitures.
Last Updated 7/31/19